3.43

1.48% 0.05

Pre-market: 3.43

Turn Therapeutics Inc (TTRX)

Overview News Price History Discussions Forecast

Turn Therapeutics Inc stock is traded at $3.43, with a volume of 41,716. It is up +1.48% in the last 24 hours and down -4.99% over the past month. Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.

Previous Close:

$3.38

Open:

$3.37

24h Volume:

41,716

Relative Volume:

1.51

Market Cap:

$102.17M

Revenue:

Net Income/Loss:

$-1.77M

P/E Ratio:

-23.07

EPS:

-0.1487

Net Cash Flow:

$-1.46M

1W Performance:

-2.00%

1M Performance:

-4.99%

6M Performance:

-32.75%

1Y Performance:

+0.00%

1-Day Range:

$3.15

$3.445

1-Week Range:

$3.09

$3.6091

52-Week Range:

$2.5701

$26.50

Turn Therapeutics Inc Stock (TTRX) Company Profile

Name

Turn Therapeutics Inc

Sector

Healthcare (1112)

Industry

Biotechnology (621)

Phone

(818) 564-4011

Address

250 NORTH WESTLAKE BLVD., WESTLAKE VILLAGE

Employee

Twitter

Next Earnings Date

2026-04-02

Latest SEC Filings

TTRX's Discussions on Twitter

Compare TTRX vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TTRX Turn Therapeutics Inc	3.43	102.17M	0	-1.77M	-1.46M	-0.1487
VRTX Vertex Pharmaceuticals Inc	441.70	112.35B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	753.93	79.71B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	840.87	52.29B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	333.39	44.48B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	319.94	35.51B	5.36B	287.73M	924.18M	2.5229

Turn Therapeutics Inc Stock (TTRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-29-25	Initiated	D. Boral Capital	Buy

Turn Therapeutics Inc Stock (TTRX) Latest News

Apr 06, 2026

Bradley Burnam holds 52.76% of Turn Therapeutics (NASDAQ: TTRX) common stock - Stock Titan

Apr 06, 2026

Head-To-Head Review: Athersys (NASDAQ:ATHX) versus Turn Therapeutics (NASDAQ:TTRX) - Defense World

Apr 06, 2026

Apr 03, 2026

Athersys and Turn Therapeutics Battle for Biotech Supremacy - National Today

Apr 03, 2026

Turn Therapeutics (TTRX) CEO-linked entity gifts 300,000 shares, retains 15.7M - Stock Titan

Apr 03, 2026

Director at Turn Therapeutics (TTRX) makes bona fide gift of 300,000 shares - Stock Titan

Apr 03, 2026

Turn Therapeutics (TTRX) CEO receives 160,000 stock options at $3.43 strike - Stock Titan

Apr 03, 2026

80K options granted at $3.12 to Turn Therapeutics (TTRX) - Stock Titan

Apr 03, 2026

[EFFECT] Turn Therapeutics Inc. SEC Filing - Stock Titan

Apr 03, 2026

Apr 02, 2026

TTRX Stock Price, Quote & Chart | TURN THERAPEUTICS INC (NASDAQ:TTRX) - ChartMill

Apr 02, 2026

Apr 01, 2026

Turn Therapeutics (NASDAQ:TTRX) Issues Earnings Results - MarketBeat

Apr 01, 2026

Strength Seen in Dianthus Therapeutics, Inc. (DNTH): Can Its 5.6% Jump Turn into More Strength? - Yahoo Finance

Apr 01, 2026

Turn Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates - BioSpace

Apr 01, 2026

Mar 31, 2026

Turn Therapeutics (TTRX) registers up to 7,000,000 shares for GEM resale - Stock Titan

Mar 31, 2026

Turn Therapeutics (TTRX) registers 17.87M shares for resale by stockholders - Stock Titan

Mar 31, 2026

Turn Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com

Mar 31, 2026

Turn Therapeutics (TTRX) details eczema drug plans and going-concern risk - Stock Titan

Mar 31, 2026

Turn Therapeutics (NASDAQ: TTRX) widens 2025 loss but secures $25M growth capital - Stock Titan

Mar 31, 2026

Mar 30, 2026

Turn Therapeutics Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com

Mar 30, 2026

Mar 25, 2026

TTRX SEC FilingsTurn Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan

Mar 25, 2026

Turn Therapeutics Secures Up to $25 Million Financing from Avenue Capital to Advance Atopic Dermatitis and Onychomycosis Programs - Minichart

Mar 25, 2026

Mar 24, 2026

Turn Therapeutics secures up to $25M in financing from Avenue Capital Group - MSN

Mar 24, 2026

D. Boral Capital Reaffirms Buy Rating for Turn Therapeutics (NASDAQ:TTRX) - MarketBeat

Mar 24, 2026

TTRX Maintains 'Buy' Rating with $8.00 Price TargetLatest Ana - GuruFocus

Mar 24, 2026

Turn Therapeutics Secures Growth Capital to Advance Dermatology - tipranks.com

Mar 24, 2026

Turn Therapeutics Secures Up to $25 Million in Financing From Avenue Capital Group - PharmiWeb.com

Mar 24, 2026

Turn Therapeutics Secures Up To $25 Million Term Loan Facility From Avenue Venture Opportunities - TradingView — Track All Markets

Mar 24, 2026

Turn Therapeutics (Nasdaq: TTRX) secures up to $25M loan facility - Stock Titan

Mar 24, 2026

Turn Therapeutics Inc. Enters into Loan and Security Agreement for Up to $25 Million Growth Capital Loan Facility with Avenue Venture Opportunities Fund Ii, L.P - MarketScreener

Mar 24, 2026

Turn Therapeutics secures $25M loan facility from Avenue Capital By Investing.com - Investing.com Canada

Mar 24, 2026

Turn Therapeutics secures $25M loan facility from Avenue Capital - Investing.com

Mar 24, 2026

Turn Therapeutics, Inc. Secures Up to $25 Million in Financing from Avenue Capital Group - marketscreener.com

Mar 24, 2026